London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Oscar-exactly!
Immupharma's presence at BIO-Europe Spring 2024 in Barcelona reflects a strategic and visionary approach from the board, highlighting the company's commitment to growth and innovation. By participating in this premier event, Immupharma seizes a critical opportunity to network with global biopharma leaders, showcasing its advanced projects like the P140 platform for SLE (Lupuzor) and the promising anti-infective asset, BioAMB. This engagement underscores the company's ongoing negotiations and pursuit of the best partnerships, signaling a robust and forward-moving trajectory.
- Explore BIO-Europe Spring 2024's significance (https://flanders.bio/en/events/bio-europe-spring-2024) (https://www.biotech.ca/event/bio-europe-spring-2024-18th-annual-international-partnering-conference/)
BIO-Europe Spring serves as an unrivaled forum for biotech companies, attracting over 3,700 leading executives and facilitating more than 20,000 partnering meetings. This proactive engagement demonstrates the company's commitment to enhancing its portfolio through strategic alliances and partnerships, highlighting its readiness to leverage every opportunity for growth. Far from a mere effort to attract attention, this move exemplifies Immupharma's dedication to advancing its ongoing discussions with potential partners, offering a comprehensive view of its potential to stakeholders worldwide.
- Learn about the event and its global reach (https://informaconnect.com/bioeurope-spring/)
The decision to attend BIO-Europe Spring is aligned with Immupharma's strategic vision, demonstrating the board's proactive efforts to position the company at the forefront of the biotech industry. It reveals a commitment not only to advancing current negotiations but also to seek new opportunities that could enhance the company's projects and shareholder value. This proactive approach in global forums like BIO-Europe Spring highlights Immupharma's dedication to making significant strides in drug development and partnerships, debunking any misconceptions about its business development activities being stagnant.
Immupharma's participation at BIO-Europe Spring 2024 is an integral component of its strategy, leveraging the event's extensive network and collaborative opportunities. This engagement is a clear indication of the company's active pursuit of partnerships and investments, reinforcing the management's dedication to driving growth and innovation within the biotech sector.
"Opportunities don't happen, you create them." — Chris Grosser
Disclaimer: This is my opinion. Do your research. Best wishes to loyal long-term holders.
Https://www.lse.co.uk/news/astrazeneca-snaps-up-rare-disease-specialist-amolyt-for-105bn-bn2r7jfi1u6ebso.html
Would they? Could they? Improbable but not impossible imo. Maybe not AZ but another large player could buy IMM on the cheap today.
"do you think Tim should have stepped up earlier ?"
Yes, the share price dropped from 1.6p-1.8p range to 0.85p in a month, and Tim should have allayed fears earlier without having to be asked by small investors here. A "we have no idea why the SP is dropping" RNS would have also sufficed earlier. Also note that the website hasn't been updated, with regards to shareholdings, since 2nd January 2024, which would also help (unless Lanstead are selling but not reporting).
With such volumes as 12.4m on March 01 and 22.8m on March 06, I cant see Flash influencing much ...in the bigger scheme of things
Dallo,
Thanks for for input on declaration...in general terms not just for here
CauldStream7,
Right on. Flash212 is just a sad clown, popping up now and then to spread his negativity like a disease. Honestly, if he's so unhappy with ImmuPharma, why stick around? If he's got any shares, which I doubt, he should just sell them. Maybe invest in a circus company; that's more his speed.
Flash, your act is tired. You're not helping, you're just a noisy stinky rat in the room. We're here for constructive discussion, not your baseless panic and misleading nonsense. So do us all a favor, sell your imaginary shares, and leave. This chat's for investors, not lousy, sad doom-mongers. This also goes of the rest of the clowns in this board! If you are not happy the door is right there, we will not stop you or miss you at all!
Alexander: As I have said before, you can't reason with Flash. You and I believe in the integrity of the IMM Board and are waiting and expecting announcements of new commercial partnerships which will finance IMM's research in the future.
Flash on the other hand has one objective: to depress the SP of IMM for as long as possible by dripping poisonous predictions of the SP falling below 1p. That is his only goal, at least on this bulletin board. But of facts he has none.
Flash, I was enjoying the well-informed dialogue from Dallo and Oscar until you decided to clown up and try lower the bar with your evident inability to grasp the situation. Your assertions about delays and funding strategies are off mark, contributing nothing but noise. It's disheartening to witness such a display of ignorance, especially when those of us who are genuinely interested in Immupharma's progress have to sift through your unfounded speculation. Do everyone a favor: try actually reading and understanding the RNS announcements before tossing around baseless claims. If you're not here to contribute meaningful insights, you might as well save your breath, here is a good start:
"Future cash requirements are fully expected to be met through non-dilutive income derived from the Company's portfolio of assets including, inter alia, new commercial deals on the development portfolio, including the non-US rights for P140 (SLE/Lupus); the worldwide rights for CIDP and for BioAMB. The Company is in active discussions with a broad range of potential commercial partners with the objective of completing deals across the portfolio in 2024." Read it again and again! You are pathetic!
Oscar
Thanks
For clarification the 1% changes relate to threshold levels ie for Lanstead that means below 15% or above 16% for example and not absolute 1% movements from existing disclosed holding...in other words a disposal of .9% by Lanstead would reduce its holding below the declarable 15% or a purchase of .12% would bring it over a declarable level of 16% .
Cheers
Hi Dallo,
You're spot on with your explanation. It matches UK's clear rules for shareholders of UK-listed companies like Immupharma, regarding the need to announce changes in their stakes. Lanstead, holding 15.89% as per the 28 December 2023 RNS, would need to issue notifications for any sale altering their position, for example:
-A sale reducing their stake by 1% to 14.89%.
- A 2% sale leading to a stake of 13.89%.
- Dropping to a 10% stake through significant sales.
This transparency maintains market integrity. For specifics, see the FCA Handbook DTR 5. FCA Handbook DTR 5 https://www.handbook.fca.org.uk/handbook/DTR/5/1.html.
Wishing all the dedicated and visionary long-term holders the very best.
Accordingly Lanstead must report any 1% or higher movements in its last notified shareholding ( c15.8%) disclosed in December 2023 in a timely manner ie 5 days or less from change or it is in breach of FCA and LSE Rules on Disclosure .
I trust this clears up the Lanstead issue.
Pokerchips
The 3% shareholding disclosure limit and subsequent 1% amounts above 3% apply to UK Issuers ie UK Incorporated listed companies and NOT foreign shareholders.
The 5% disclosure levels apply to shareholdings in Non-UK Issuers ie foreign Incorporated companies listed on the LSE.
The requirements to adhere to these regulations apply to all shareholders regardless of their residency status.
Dallo
thanks for your post..interesting .... I did notice that Landstead have put "non uk issuer" on more than one occasion
certainly if you were a US investor they declare at 5% and every 5% whilst UK investors declare at 3% and every 1% so there is a difference ....you see it with the likes of JPM and Morgan Stanley etc
who do you think was behind the selling that has gone on from Jan to March , before Tim finally stepped in ..do you think it was all just private investors , and if so, you do think Tim should have stepped up earlier ?
regards
Pokerchips
Lanstead is not "a Non-UK Issuer" for UK reporting purposes but a foreign shareholder like me and millions of others in a UK company listed on the London Stock Exchange.
Immupharma is a UK Issuer for TR-1 Forms reporting changes in notifiable holdings by shareholders whether UK or foreign and notified both to the Issuer ( Immupharma) and the FCA.
Lanstead made an error in its TR-1 Form last December by stating Immupharma was a "Non-UK Issuer " which may be where you got confused.
I have submitted a number of TR-1 Forms in respect of a shareholding in a Non-UK Issuer in the past 4 years and , as a Non UK national, I have the exact same reporting requirements as a UK investor.
Otherwise with millions of Non UK Investors in the LSE, it would be outrageous to allow relaxed rules for foreign investors as this would be against International regulatory, money laundering ,US FATCA Act et al.
"Lanstead appear be dumping, bit of a worry"
Steven49
if Landstead were selling then that would be an expectation from them , if you understand who they are .....so it would not really be a worry ..more like something that had been anticipated
" Here are the facts Lanstead held 15.8% as of December 2023 and it must issue a holdings RNS if its holding goes below 15% under Stock Exchange rules. "
Dallo
Landstead is a Non-UK issuer and does not follow the same % declaration rules which apply to a UK-Issuer
Landstead have often sent a TR-1 even with very small % changes
If it were Landstead selling then I suspect they would issue a TR-1 when they have finished/reached their target % point ..indicating they werent intending to sell further as a result of the TR-1
I suspect if they are selling they may well have appointed a broker to do the selling for them, and instructed the broker as to how many shares they would like to sell....
ATB
If a UK issuer were to not notify a company in a timely fashion then they may lose the Voting Rights on what shares they hadnt declared at any forthcoming AGM but it is normally something a company would deal with ....as it is a matter between the buyer/seller and the company involved
Steven
Again another silly piece of conjecture on your part
Here are the facts Lanstead held 15.8% as of December 2023 and it must issue a holdings RNS if its holding goes below 15% under Stock Exchange rules.
So far Lanstead hasn't done so which makes your comment about Lanstead dumping shares extremely circumstantial and frankly utterly useless to the debate.
Cheers to Oscar, CauldStream7, Dallo, Ginhall for cutting through the fog with pure RNS facts and constructive comments. To the losers prophets of doom, ever wonder why you're here, relentlessly peddling negativity and false rumours? Is this your idea of fun, or are you just lost or sad or bitter inside? This board isn't your personal circus, we know you are all lousy clowns but real investors are here for grounded discussions. If spreading gloom is your agenda, maybe you're in the wrong place. IMM's path is for those who get the stakes with a vision, not for those who mistake it for a soapbox to shout from. Silence isn't just golden for the clueless—it's a courtesy. Can't align with that? There's the door, don't expect anyone to hold it for you! Your repetitive, hollow rants? Utterly tedious! Maybe it's time to educate yourself instead of polluting the airwaves. Boring losers!
Lanstead appear be dumping, bit of a worry
Wildbunch
Nobody should fear divergent views on shares and everyone has their opinions but on a share forum when you see scaremongering about liquidation or another death spiral placing from posters with no investment in Immupharma, you have to query their motives.
What satisfaction do these people get out of opining on the demise of Immupharma without looking at the positive progress made in the past 2 years since we got the Alora Group on board , got rid of Zimmerman, Dimitriou et al and worked assiduously on a formula for Lupuzor trial with the US FDA and expanded Immupharma's suite of drugs to include CIDP and the Anti Infectives plus finally seeing great potential in Incanthera's Sol anti cancer suncream now being distributed through the largest cosmetic chain , AS Watson part of the mega CK Hutchison Group.
Also according to the naysayers 2 weeks ago, Immupharma could not get funding but now have possibly 3 sources should it need it....Warrants, Commercial deals or Incanthera financial asset.
At a market cap of c£5m surely even the doomsday scenarios look absurd.
At least Lambo the arch bear has had the decency to withdraw from the discussions.
ATB
Flash
If you are concerned about Immupharma and fear losing your money, in your view, in a bad stock then my simple advice is...DONT BUY ANY SHARES IN THE COMPANY.
ATB
Dallo, CS7-there is no reasoning with Flash or PC-they have nothing interesting to say-hence my filtering them.
They never seem to place any weight on the deal we already have regarding Lupus, the progress re CIPD, the appointment of Reilly, the other possibilities in the pipeline. They harp on about dilution and working capital and T McC-all reasonable points if considered with the positive fundamentals.
I have averaged down-bought another 300,000 this week. I anticipate more good news about the progress of the Lupus trial, the results of discussions with FDA about CIDP and the blossoming to the INC share price, the ROTW rights, in the coming few months.
That's all.
GLA proper investors!
11% plus up today. Shorters are desperate.
GH.
Pokerchips
Doesn't worry me at all because I have added to my holding in past 2 weeks at below 1.2p so won't be diluted from previous levels.
In the context of the liquidation/ heavily discounted placing fears of 2 weeks ago, I will accept the exercise of the 2p warrants given that the SP would have to be much higher than 2p for a sustained period before warrant holders can be persuaded to exercise.
ATB
Pokerchips;
No one said that financing for a small pharma comes cheaply, so yes, and extra £2m in exchange for 100 million shares is a high price to pay. This is about survival with the goal being multi million bucks when the phase 3 trials are successful and deals are struck with other pharmas for the development for the drugs in the IMM pipeline.
That is why I still buy shares because the share price is below the 2p level which not so long ago was seen as unbelievably cheap. Hopefully we will soon see these ultra low prices recede into the past and the price will head back into double figures.